# Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

*PRI Rank #16 · Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026/rank-16*

| Field | Value |
| --- | --- |
| Rank | #16 |
| 18m citations | 29 |
| Journal | The Lancet Oncology |
| Year | 2024 |
| DOI | 10.1016/s1470-2045(24)00004-4 |
| Corresponding authors | Carlo Palmieri |
| Institution | The University of Liverpool, United Kingdom |

**Ranking page:** [Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026](https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026)

**Paper link:** [10.1016/s1470-2045(24)00004-4](https://doi.org/10.1016/s1470-2045(24)00004-4)

## Topics

enobosarm · selective androgen receptor modulator · androgen receptor · estrogen receptor-positive breast cancer · HER2-negative breast cancer · AR-positive disease · ER-positive advanced breast cancer · androgen receptor as tumour suppressor · clinical benefit rate · menopause · advanced breast cancer · AR activation · drug-induced liver injury · hypercalcaemia · endocrine therapy · Bone metastases · phase 2 trial · selective androgen receptor modulator

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```